LOUISVILLE, CO, March 25, 2008 – GlobeImmune, Inc. announced today the addition of J. William Freytag, Ph.D. to its Board of Directors. “Dr. Freytag brings over 25 years of research, product development and commercialization experience to the Board,” said Timothy … Continue reading
FOR IMMEDIATE RELEASE GlobeImmune Announces Initiation of a Phase 2a Clinical Trial of GI-4000 in Patients with Non-Small Cell Lung Cancer at Memorial Sloan Kettering LOUISVILLE, CO, March 19, 2008 – GlobeImmune, Inc. announced today the initiation of a Phase … Continue reading
FOR IMMEDIATE RELEASE: LOUISVILLE, CO – January 3, 2007 – GlobeImmune, Inc. announced today that President and Chief Executive Officer Timothy C. Rodell, M.D. will present at the JPMorgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco … Continue reading
LOUISVILLE, CO, December 19, 2007 – GlobeImmune, Inc. announced today the initiation of the Company’s Phase 2 clinical trial to evaluate GI-5005 Tarmogen® for the treatment of patients with chronic hepatitis C infection. GI-5005 is being evaluated as a potential … Continue reading
LOUISVILLE, CO, November 6, 2007 – GlobeImmune, Inc. today announced results from the additional higher dose cohorts from the Company’s randomized, placebo-controlled Phase 1b clinical trial evaluating the safety, immunogenicity and initial efficacy of GI-5005 in patients with chronic hepatitis … Continue reading
LOUISVILLE, CO, November 1, 2007 – GlobeImmune, Inc. today announced that additional high dose results from the Company’s randomized, placebo-controlled Phase 1b clinical trial evaluating GI-5005 as a treatment of chronic hepatitis C infection will be the subject of a … Continue reading
LOUISVILLE, CO, October 25, 2007 – GlobeImmune, Inc. announced today results from research on its GI-10001 Tarmogen®, which is being investigated for the treatment of drug resistant chronic myelogenous leukemia (CML). Leukemia driven by the Bcr-Abl T315I mutation, known as … Continue reading
LOUISVILLE, CO, September 26, 2007 GlobeImmune Inc. today announced it has raised $41.2 million through a Series C Preferred Stock financing. This round was led by Wexford Capital LLC, and as a result of its investment, Paul A. Mieyal, Ph.D. … Continue reading
LOUISVILLE, CO, January 5, 2007, GlobeImmune, Inc. announced today that President and Chief Executive Officer Timothy C. Rodell, M.D. will present at the JPMorgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 10, 2007 … Continue reading
LOUISVILLE, CO, October 30, 2006, GlobeImmune, Inc. today announced positive interim results from Study GI-5005-01, a randomized, placebo-controlled, multi-center, dose-escalation, Phase 1b study of GI-5005 in patients chronically infected with hepatitis C virus (HCV). The data were presented today at … Continue reading